Business Context and Reporting Period
This Form 8-K Current Report was filed by Acurx Pharmaceuticals, Inc. on September 22, 2025. The report discloses corporate governance actions taken at a special meeting of stockholders held on September 16, 2025, and the subsequent filing of an amendment with the Delaware Secretary of State.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a capital structure amendment and does not contain financial performance data.
Material Changes
- Authorized Share Increase: Stockholders approved an amendment to the Certificate of Incorporation increasing the total number of authorized common shares from 200,000,000 to 250,000,000.
- Effective Date: The amendment was filed with the State of Delaware on September 22, 2025, and became effective immediately.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the procedural details of the share authorization amendment.
Investor Verification Checklist
- Verify the exact number of authorized shares increased to 250,000,000.
- Confirm the filing date of the amendment with the Delaware Secretary of State (September 22, 2025).
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for any additional terms not summarized in the 8-K.
- Check subsequent filings for any immediate issuance of shares from the newly authorized pool.